1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6015B563193067C1A8525713F006CFAE0
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharma-rd-quality-assurance-staffing-and-use-of-risk-based-approach-programs?opendocument
18
19opendocument
2034.229.76.193
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Benchmarking and Quality Quality Quality Teams

Pharma R&D Quality Assurance: Staffing and Use of Risk-Based Approach Programs

DB Image

ID: 4884


Features:

Metrics, Graphics


Pages/Slides: 39


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Pharma R & D Quality Assurance: Staffing and Use of Risk-Based Approach Programs"


Study Overview:

This study is aimed at helping pharmaceutical R&D Quality Assurance executives tackle two current challenges: optimizing limited QA staff resources and implementing Risk-Based Approach guidelines for GxP oversight. This study identifies ratios of QA organization size relative to the size of the R&D functional areas they serve. Organizations are also evaluated on their level of Risk-Based Approach and its impact on QA workload and management.

QA leaders can use this 39-slide presentation to gauge their staffing levels as well as FTE distribution across the GCP, GLP and GMP functions. They will also get a look at where pharma companies are today in preparing for risk-based assessment.

Key Metrics and Topic Areas:

  • Average ratio of R&D QA employees to all R&D employees supported
  • Optimal QA staffing distribution by function, including GMP, GLP, GCP, Pharmacovigilance QA, API, Inspections Administration
  • Percentage of total QA employees staffed to various R&D functional roles (e.g. clinical research, manufacture of API for clinical trial use, etc.)
  • Optimal ratio of QA supervisors to QA front-line staff
  • Average percentage of R&D activities that are outsourced
  • Risk-Based Approach implementation of each benchmark partner: tools, application and impact


Note: A related document, #4888, Pharmaceutical Case Studies in Adopting a Risk-Based Approach, provides much greater detail about these companies' implementation of a Risk-Based Approach. For each of the six profiled companies, it includes 1) the status of RBA; 2) tools used; 3) scoring system; 4) risk parameters; 5) impact of RBA; 6) information sharing; and 7) perspective on ICH Guidance Q9.

Sample Key Findings:

  • The QA to R&D Activity staffing ratios demonstrate that quality oversight resources for each pharmaceutical R&D activity vary widely from company to company.
  • Most companies are carrying their implementation of Risk-Based Approach into each GxP area. However, these companies commonly characterize their implementation of Risk Based Approach in different QA areas as “Under Development,” indicating that formal RBA programs are relatively new.
  • Based on survey responses and descriptions of formal Risk-Based Approach implementation programs, most companies appear to have a greater understanding of how RBA can be used in GMP and GLP oversight, but have less understanding of its application to GCP.

Methodology:

Best Practices, LLC conducted surveys and follow-up interviews with six leading pharmaceutical companies. The study was completed for a Global Benchmarking Council member.

Industries Profiled:
Pharmaceutical; Health Care; Medical Device


Companies Profiled:
Abbott Laboratories; Novartis; Johnson & Johnson; Eli Lilly; Boehringer-Ingelheim


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.